Amneal Romidepsin FDA Approval Analysis
Decision brief
Answer first · skim in under a minute
Amneal won FDA approval for ready-to-use romidepsin 27.5 mg/5.5 mL with 180-day CGT exclusivity for CTCL after prior systemic therapy.
Amneal Pharmaceuticals received U.S. FDA approval for a ready-to-use romidepsin injection solution on June 4, 2026, restoring a convenient liquid presentation for cutaneous T-cell lymphoma after prior systemic therapy. This Amneal romidepsin FDA approval analysis focuses on 180-day CGT exclusivity, formulation differentiation, and BD diligence—not unsourced PTCL claims.
Contents10 sections
Key Takeaways
- GlobeNewswire: Amneal’s romidepsin injection solution 27.5 mg/5.5 mL won FDA approval on June 4, 2026, in single-dose ready-to-use vials.
- Indication in the company release: cutaneous T-cell lymphoma (CTCL) in adults after at least one prior systemic therapy; HDAC inhibitor class.
- Competitive Generic Therapy eligibility confers 180 days of exclusivity from first commercial marketing, per Amneal.
- Product references Teva’s withdrawn ready-to-use solution; convenience versus lyophilized powder is the hospital-pharmacy differentiator.
What exactly did Amneal announce?
In a June 4, 2026 GlobeNewswire release, Amneal (Nasdaq: AMRX) said FDA approved romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials. The company positioned the liquid presentation as a more convenient alternative to lyophilized powder that requires reconstitution.
Amneal also said the product is eligible for Competitive Generic Therapy (CGT) designation with 180 days of market exclusivity and that it references the former Teva romidepsin solution withdrawn years earlier. Those are the primary commercial facts BD teams should lock before modeling share.
How does the FDA label frame clinical use?
Historical prescribing information for romidepsin products describes HDAC inhibition and CTCL use after prior systemic therapy. Teams should verify Amneal’s final labeling on FDA channels rather than assume peripheral T-cell lymphoma (PTCL) coverage remains active on every presentation.
DailyMed and Drugs@FDA remain the authoritative label hosts. A representative legacy label PDF on FDA’s site is available via accessdata.fda.gov romidepsin labeling; confirm Amneal’s NDA/ANDA label text at launch for boxed warnings, QT monitoring, and dosing.
OpenFDA label search endpoints also support programmatic checks against the openFDA drug label API once Amneal’s set-id appears.
Why does 180-day CGT exclusivity matter for BD?
CGT exclusivity is designed to reward first competitive generic entry in limited-competition categories. For Amneal, the 180-day window is the period to secure hospital contracts and GPO formulary slots before additional ANDA competitors arrive.
- Clock start: first commercial marketing date, not approval date alone.
- Formulation edge: ready-to-use vials may win pharmacy operations preference even if acquisition cost is only modestly below brand or lyophilized generics.
- Volume reality: CTCL is a niche oncology market; absolute dollar upside is constrained versus mass-market injectables.
What safety themes should launch teams watch?
Romidepsin carries well-known class and product risks, including QT-interval monitoring requirements historically highlighted in prescribing information. A 2026 PubMed-indexed analysis discussing hypophosphatemia as a potential HDAC-inhibitor class effect is available at PubMed 42198363; treat it as a pharmacovigilance signal for monitoring policy, not a new boxed warning invented here.
Risk Evaluation materials and hospital REMS-adjacent workflows (if any) should be reviewed against Amneal’s launch kit before assuming parity with prior Teva or brand operations.
How should investors weigh Amneal’s injectables strategy?
Amneal framed the approval as expanding a differentiated injectables portfolio and noted that, since FDA began tracking CGT approvals in 2018, the company has received the most CGT approvals in the industry—an Amneal claim investors can verify against FDA CGT lists rather than accept as market share proof.
For partnering diligence, separate (1) hospital pharmacy preference for ready-to-use vials, (2) the finite 180-day exclusivity clock, and (3) long-run ANDA competition after exclusivity. Niche CTCL volumes mean execution quality in specialty distribution matters more than consumer-style launch marketing.
Compare contracting timelines with prior Amneal institutional launches and ask whether 340B and outpatient infusion reimbursement pathways are already mapped for the 27.5 mg/5.5 mL SKU.
What remains unproven?
The GlobeNewswire release does not disclose U.S. peak sales guidance, payer coverage decisions, or PTCL labeling for Amneal’s specific presentation. Delete claims that Amneal automatically captures “majority share of ISTODAX” or that PTCL remains on-label unless the FDA label for this SKU says so.
Related NovaPharma coverage
- Romidepsin drug profile
- Gene therapy FDA approval list analysis
- FDA approves lumasiran: BD implications
Frequently Asked Questions
What did FDA approve for Amneal’s romidepsin?
On June 4, 2026, Amneal announced FDA approval of romidepsin injection solution, 27.5 mg/5.5 mL, in single-dose ready-to-use vials as a histone deacetylase inhibitor for adults with cutaneous T-cell lymphoma after at least one prior systemic therapy.
How long is Amneal’s CGT exclusivity?
Amneal said the product is eligible for Competitive Generic Therapy designation providing 180 days of market exclusivity, timed from first commercial marketing under FDA’s CGT framework.
What reference product does Amneal cite?
Amneal stated its ready-to-use solution references the former romidepsin solution formulation previously marketed by Teva, which was withdrawn from the market several years ago.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Romidepsin.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
